IPO UPDATE
Following up on our April 2025 update, I’m pleased to share further details on our go-public transaction and the exciting opportunities we are pursuing as part of our next phase of growth.
Our Go-Public Strategy
After careful consideration, we have made the strategic decision to pursue a direct listing on NASDAQ, supplemented by PIPE (Private Investment in Public Equity) funding. We believe this approach provides the most efficient path to achieve our go-public goals, and we are taking the following critical steps to position ourselves for success:
-
New Legal Counsel: We have engaged Sichenzia, Ross, Ference, & Carmel, a leading SEC law firm, to guide us through the listing process. Ross Carmel, one of their senior partners, has been recognized as a Super Lawyer Rising Star by Thomson Reuters from 2017 through 2021, bringing invaluable expertise to our team, especially with direct listings on senior exchanges.
-
PIPE Funding: We have entered into an updated engagement agreement with Joseph Gunnar & Co. to raise the necessary PIPE funding and assist with the NASDAQ listing process.
-
S-1 Filing & Financial Review: Our team is working diligently to update our S-1 registration statement to reflect our new go-public strategy. We are also
undergoing the required Q1 financial review, which will be filed alongside our
audited financials for 2023 and 2024.
-
Third-Party Valuation: In compliance with the requirements for a direct listing, we have engaged Valuescope, a highly regarded business valuation firm, to conduct an independent valuation of our company. After evaluating six firms, we selected Valuescope for their extensive experience with senior exchange listings. We are satisfied with the final valuation, which will be incorporated into our updated S-1.
Expanding Health & Wellness Focus
As we look ahead, we see tremendous potential in aligning our future growth with the rapidly expanding Health & Wellness sector. The recent Presidential Executive Order on Making America Healthy Again (February 13, 2025) positions our company to play a significant role in this transformation. Our Kirkman brand has a rich history of producing clean, effective nutraceuticals for over 40 years, specifically focused on families with children on the Autism Spectrum.
We are proud to have been the first company to partner with Dr. Bernie Rimland, a
pioneer in autism research, and we see a unique opportunity to re-market our products to this growing community. The funds raised through our PIPE funding will allow us to continue innovating, expanding, and driving growth in this critical area.
Autism prevalence continues to rise, with the CDC’s 2023 report indicating that 1 in 31 children is now diagnosed with autism, up from 1 in 150 in 2000. This demographic shift creates an ever-growing demand for our specialized products, and we are committed to meeting that need.
Additionally, we are particularly excited about the launch of P2i by Kirkman—our
certified prenatal vitamin, which aligns fully with the FIGO (International Federation of Gynecology and Obstetrics) position statements on prenatal supplementation. This product will help us capitalize on the increasing global demand for safe, scientifically-backed health solutions for expecting mothers.
Investor Appreciation
I want to take a moment to express my sincere gratitude for your ongoing trust,
investment, and support as we move forward with this pivotal moment in our company’s growth. Rest assured, we are closely managing costs and have a solid marketing strategy in place to ensure we can deploy the PIPE funding effectively to drive both revenue and profitability.
Closing Thoughts
Thank you for being a crucial part of our journey. Together, we are not just building a
financially strong future, but also advancing a shared commitment to improving health and wellness for families across the globe. I look forward to keeping you updated on our progress and the exciting milestones to come.
